Lung Cancer

Lung Cancer Screening: Rates Remain Low and Disparities Run High

By

Tori Rodriquez, MA, LPC, AHC

Publish Date December 30, 2019

Despite resources, lung cancer screening with low-dose computed tomography remains underutilized.

Vaping Injuries Raise New Concerns About Medical Marijuana

By

Bryant Furlow

Publish Date November 19, 2019

Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.

Pharmacovigilance Needed for Immune Checkpoint Inhibitor Therapy in NSCLC

By

Tori Rodriguez, MA, LPC, AHC

Publish Date August 28, 2019

Immune checkpoint inhibitor therapies have improved survival in patients with non-small cell lung cancer, but they have also been linked to immune-related adverse events affecting various organs, including the lungs.

Entrectinib May Eventually Be an Option for ROS1 Fusion-Positive NSCLC

Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.

Study Supports Standard-Dose RT in Chemoradiotherapy for Some Patients With NSCLC

Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.

Lung Cancer Risk Increased Among Individuals Living in Disadvantaged Neighborhoods

Individuals of low socioeconomic status who reside in disadvantaged neighborhoods with poor living conditions may be at higher risk for lung cancer.

High BMI Linked to Survival in NSCLC Treated With Atezolizumab

Baseline high body mass index was associated with improved survival in patients with non-small cell lung cancer treated with atezolizumab.

Many Patients With Lung Cancer Receive QTc-Prolonging Medications

Receipt of these medications prolonging corrected QT interval limits patients’ eligibility for clinical trials.